Clinical Trials · NCT00108732
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 50
- Start date
- Feb 2006
- Locations
- 7 sites, United States
- Primary endpoint
- Proportion of Patients Free of PSA Progression at 6 Months (Prior to the Start of Androgen Ablation)